Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.

IsoPlexis, a US-based proteomics platform spun out of and backed by Yale University, has filed to raise up to $100m in an initial public offering. Founded in 2013, IsoPlexis has developed a single-cell proteomics platform used to study proteins and single-cell biology for the purpose of cancer immunology, cell and gene therapy development. The spinout’s…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.